Biotek-snakken — December 2021
-
Data er opdateret med 8 patienter og PFS. Posteren kan i øvrigt ses her: https://ir.zymeworks.com/static-files/27a4e19c-3cc8-4005-ade2-e42f01e4bc69
-
SMS Rammeaftale med Health-Tech gigant sikrer pipeline med "tocifret"
millionomsætning https://www.proinvestor.com/boards/99355/SMS-Rammeaftale-med-Health-Tech-gigant -
-
3 Under-the-Radar Biotech Stocks to Buy in 2022 https://www.proinvestor.com/investornyt/748197/3-under-the-radar-biotech-stocks-to-buy-in-2022
-
Is It Too Late to Buy Moderna Stock? https://www.proinvestor.com/investornyt/748313/is-it-too-late-to-buy-moderna-stock
-
Novartis : Kymriah Shows Strong Responses In High-risk Patients With Relapsed Or Refractory FL https://www.proinvestor.com/investornyt/748293/novartis-kymriah-shows-strong-responses-in-high-risk-patients-with-relapsed-or-refractory-fl
-
3 Biotech Stocks That Could Make You Richer in December (and Beyond) https://www.proinvestor.com/investornyt/748319/3-biotech-stocks-that-could-make-you-richer-in-december-and-beyond
-
Novartis' Updated ASCEMBL Study Showed Sustained Efficacy Vs Bosutinib In Chronic Myeloid Leukmia
https://www.proinvestor.com/investornyt/748367/novartis-updated-ascembl-study-showed-sustained-efficacy-vs-bosutinib-in-chronic-myeloid-leukmia -
Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years following Hemophilia A gene therapy...https://www.proinvestor.com/investornyt/748387/pfe-phase-1-2-results-show-bleeding-control-in-highest-dose-cohort-after-hemophilia-a-gene-therapy
-
Australia's CSL Confirms Takeover Talks With Swiss Drugmaker Vifor Pharma https://www.proinvestor.com/investornyt/748402/australias-csl-confirms-takeover-talks-with-swiss-drugmaker-vifor-pharma
-
ASH21: Precision Bio's allogeneic CAR T therapy faces durability issues https://firstwordpharma.com/story/5460395
-
Sanofi, Alnylam's fitusiran hits bleeding endpoints in haemophilia studies https://firstwordpharma.com/story/5448781
-
AstraZeneca Elated On Calquence Data,
IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch https://www.proinvestor.com/investornyt/748420/astrazeneca-elated-on-calquence-data-imgns-imgn632-appears-to-be-promising-in-aml-xrtx-on-watch -
Roche Unveils New Automated AVENIO Edge System - Quick Facts https://www.proinvestor.com/investornyt/748425/roche-unveils-new-automated-avenio-edge-system-quick-facts
-
Regeneron : Phase 3 Results Show Dupixen Improved Skin Clearance In Children With Atopic Dermatitis https://www.proinvestor.com/investornyt/748426/regeneron-phase-3-results-show-dupixen-improved-skin-clearance-in-children-with-atopic-dermatitis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind